Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Filgotinib in Idiopathic Multicentric Castleman's Disease
jRCTs071230120Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of filgotinib in idiopathic multicentric Castleman disease (iMCD), sponsored by Gilead Sciences. Primary endpoint: Safety and tolerability of long-term filgotinib. Started Mar 2024; status: completed.
02
Drugs
filgotinib
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on jRCTs071230120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230120.